MENU

IPHA Stock Innate Pharma SA (IPHA, $3.02) price may drop as it broke higher Bollinger Band on Dec 13, 2024

A.I.dvisor
at Tickeron.com
Loading...
IPHA - Innate Pharma SA
Bollinger signal
Bearish Trend
Odds of DOWN Trend
Tickeron
Bollinger signal
Price: $3.02
Daily change: +$1.47 (+94.84%)
Daily volume: 13.6M
Capitalization: $134.4M
Industry: Biotechnology
This price move could be a signal that IPHA may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options. A.I.dvisor backtested 34 similar cases where IPHA's price broke its higher Bollinger Band, and of them led to a successful outcome. Odds of Success:

IPHA saw its Stochastic Oscillator peaks and leaves the overbought zone

The Stochastic Oscillator for IPHA moved out of overbought territory on December 12, 2024. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 50 similar instances where the indicator exited the overbought zone. In of the 50 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for IPHA moved out of overbought territory on December 16, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 12 similar instances where the indicator moved out of overbought territory. In of the 12 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IPHA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

IPHA broke above its upper Bollinger Band on December 13, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on December 09, 2024. You may want to consider a long position or call options on IPHA as a result. In of 119 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for IPHA just turned positive on December 06, 2024. Looking at past instances where IPHA's MACD turned positive, the stock continued to rise in of 56 cases over the following month. The odds of a continued upward trend are .

IPHA moved above its 50-day moving average on December 13, 2024 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for IPHA crossed bullishly above the 50-day moving average on December 16, 2024. This indicates that the trend has shifted higher and could be considered a buy signal. In of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +3 3-day Advance, the price is estimated to grow further. Considering data from situations where IPHA advanced for three days, in of 233 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 115 cases where IPHA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IPHA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.889) is normal, around the industry mean (14.294). P/E Ratio (0.000) is within average values for comparable stocks, (87.370). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.766). IPHA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (6.653) is also within normal values, averaging (256.769).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IPHA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
IPHA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
117, Avenue de Luminy
Phone
+33 430303030
Employees
211
Web
https://www.innate-pharma.com